Obalon Therapeutics Inc.

Obalon Therapeutics rockets on clinical data showing its Obalon Balloon System works safely to treat obesity

The San Diego company says average weight loss for patients receiving three balloons and six months of therapy was nearly 22 pounds

Obalon tested the balloon system on more than 1,400 patients

Shares of Obalon Therapeutics Inc (NASDAQ:OBLN) more than doubled Wednesday after the medical-device company released more clinical data affirming the effectiveness and safety of its flagship Obalon Balloon System to treat obesity.

The expanded clinical data, complied during a large-scale commercial-uses study of more than 1,400 patients, indicated that average weight loss for patients receiving three balloons and six months of therapy was 21.7 pounds, resulting in a 10.2% reduction in total body weight, according to a statement.

Investors cheered the positive data, sending Obalon’s stock up 233% to $1.30 a share at the close on massive trading volume of 69 million shares.

READ: Obalon Therapeutics shares plunge after bigger-than-expected 1Q loss on sliding revenue

Obalon, based in San Diego, also noted that 50.7% of patients lost at least 10% total body weight and 77.9% lost at least 5%.

Non-serious adverse events occurred in 10.3% of the patients with the most common being abdominal pain (3.8%), nausea (3.0%), and vomiting (1.7%). And there were no serious adverse events (SAEs) reported, Obalon said.

The company presented the expanded data at the Digestive Disease Week 2019 Annual Conference in San Diego, which ended Tuesday.

“The Obalon Balloon registry is the largest endoscopic bariatric therapy registry series in the US,” said Shelly Sullivan, director of the Gastroenterology Metabolic and Bariatric Program at the University of Colorado School of Medicine. “The additional data collected showed significant weight loss in patients treated with this therapy in clinical practice with a good safety profile. These results remain consistent with our previous publications.”

With Obalon’s stock now trading above $1 a share, it should avoid being delisted on the Nasdaq. On May 16, the company received a delisting notification letter from Nasdaq as companies whose share prices fall below $1 typically get the notices. Obalon also received another delisting letter from Nasdaq this month about stockholders’ equity falling below the minimum threshold of $10,000,000, which the stock rally should help negate as well.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Obalon Therapeutics Inc.

Price: $2.16

Market: NASDAQ
Market Cap: $12.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

1 day, 3 hours ago

2 min read